Minimal residual disease (MRD) continues to be a central focus at the AACR meeting. The small numbers of cancer cells that ...

New protocol generated glucose-responsive SC-islets from eight hPSC lines tested, demonstrating potential for autologous ...

Gene‑edited HPSCs programmed to make therapeutic antibodies and proteins show long‑lasting, boostable immunity in mouse models.

Harnessing technology transferred from VTT Technical Research Centre of Finland, Proteins.1 is developing a PCR-like ...

AACR chairs Paul Mischel and Alice Shaw shared insights with GEN on the key themes shaping this year’s program.

Rarely, some nanoparticles that enter a cell undergo an unexpected transformation, acquiring a coating known as a “condensate ...

Daraxonrasib improved survival in metastatic pancreatic cancer in Phase III, signaling meaningful progress for therapies targeting RAS‑driven disease.

The new Fujifilm Biotechnologies QC Lab features ventilation systems, personnel, and material airlocks, and an open‑plan layout.

Researchers say knowing that semaglutide improves liver health independently of weight loss could influence prescribing decisions.

The dosing of these two patients demonstrates Cellares’ GMP manufacturing and supply chain capabilities with their automated platform.

A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.

Regeneron Pharmaceuticals plans to expand its pipeline into radiopharmaceutical therapies through an up to $4.3 billion collaboration with Telix Pharmaceuticals to co-develop and co-commercialize ...